AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16235834 — intervention group
Group type: EXPERIMENTAL
Intervention: Small dense LDL (sdLDL) prevalence rate analysis
Number of subjects: 0
Study 16235834 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of Type 2 DM classified by HbA1c value
Number of subjects: 0
Study 16235834 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence rate of sdLDL in relation to complications (microangiopathy and macroangiopathy)
Number of subjects: 0
Study 16235834 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of sdLDL with serum TG level
Number of subjects: 0
Study 16235834 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum level of TG-rich remnants
Number of subjects: 0
Study 16235834 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of sdLDL
Number of subjects: 0
Study 16235834 — intervention group
Group type: EXPERIMENTAL
Intervention: Conclusion on sdLDL levels
Number of subjects: 0
Study 16235834 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of sdLDL with severity and modalities for complications
Number of subjects: 0
Study 12172896 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin protection measures (SP), no specific dosage or duration mentioned
Number of subjects: 94
Study 12172896 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet B (UVB) hardening, no specific dosage or duration mentioned
Number of subjects: 94
Study 12172896 — intervention group
Group type: COMPARATOR
Intervention: No intervention (controls)
Number of subjects: 94
Study 10213261 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol delivered by metered dose inhaler (MDI) and spacer
Number of subjects: 8
Study 10213261 — intervention group
Group type: COMPARATOR
Intervention: Albuterol delivered by low-flow nebulizer (NEB)
Number of subjects: 8
Study 10213261 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MDI and NEB
Number of subjects: 8
Study 7794851 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg dydrogesterone
Number of subjects: 371
Study 7794851 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dydrogesterone
Number of subjects: 371
Study 7794851 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg dydrogesterone
Number of subjects: 371
Study 7794851 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg dydrogesterone
Number of subjects: 371
Study 7794851 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses
Number of subjects: 371
Study 7794851 — intervention group
Group type: EXPERIMENTAL
Intervention: At least 10 mg dydrogesterone
Number of subjects: 371
Study 1977371 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (80 mg/d orally for 5 days)
Number of subjects: 12
Study 365122 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 0
Study 365122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30448166 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 70
Study 30448166 — intervention group
Group type: COMPARATOR
Intervention: Control (sham procedure)
Number of subjects: 70
Study 28244495 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenapanor 50 mg b.i.d.
Number of subjects: 356
Study 28244495 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenapanor 20 mg b.i.d.
Number of subjects: 356
Study 28244495 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenapanor 5 mg b.i.d.
Number of subjects: 356
Study 28244495 — intervention group
Group type: COMPARATOR
Intervention: Placebo b.i.d.
Number of subjects: 356
Study 23914770 — intervention group
Group type: EXPERIMENTAL
Intervention: Shockwave lithotripsy (SWL)
Number of subjects: 180
Study 23914770 — intervention group
Group type: EXPERIMENTAL
Intervention: Semirigid ureteroscopy (URS)
Number of subjects: 180
Study 23914770 — intervention group
Group type: EXPERIMENTAL
Intervention: Shockwave lithotripsy (SWL) for stones <10 mm
Number of subjects: 180
Study 23914770 — intervention group
Group type: EXPERIMENTAL
Intervention: Semirigid ureteroscopy (URS) for stones <10 mm
Number of subjects: 180
Study 23914770 — intervention group
Group type: EXPERIMENTAL
Intervention: Shockwave lithotripsy (SWL) for stones 10 to 20 mm
Number of subjects: 180
Study 23914770 — intervention group
Group type: EXPERIMENTAL
Intervention: Semirigid ureteroscopy (URS) for stones 10 to 20 mm
Number of subjects: 180
Study 22502601 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% sodium hypochlorite (NaOCl)
Number of subjects: 65
Study 22502601 — intervention group
Group type: COMPARATOR
Intervention: 1:5 dilution of Buckley's formocresol (FC)
Number of subjects: 65
Study 21871113 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary plan with an energy deficit of 1200 kcal/day, strengthening exercises (15 min/hour), cognitive behavioral training (30 min/hour) during working hours 1 hour/week, leisure time aerobic fitness for 2 hour/week
Number of subjects: 98
Study 21871113 — intervention group
Group type: COMPARATOR
Intervention: Monthly oral presentations
Number of subjects: 98
Study 19720797 — intervention group
Group type: EXPERIMENTAL
Intervention: Ala carriers (Ala/Ala or Ala/Pro)
Number of subjects: 1119
Study 19720797 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro/Pro homozygotes
Number of subjects: 1119
Study 19720797 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitor therapy in Pro/Pro homozygotes
Number of subjects: 1119
Study 19720797 — intervention group
Group type: COMPARATOR
Intervention: Non-ACE inhibitor therapy in Pro/Pro homozygotes
Number of subjects: 1119
Study 17904939 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic low-carbohydrate diet
Number of subjects: 0
Study 17904939 — intervention group
Group type: COMPARATOR
Intervention: Control diet (nonketogenic)
Number of subjects: 0
Study 15472678 — intervention group
Group type: EXPERIMENTAL
Intervention: Transpancreatic septotomy sphincterotomy (n = 29)
Number of subjects: 63
Study 15472678 — intervention group
Group type: COMPARATOR
Intervention: Needle-knife sphincterotomy (n = 34)
Number of subjects: 63
Study 11464180 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized isotretinoin (0.4 mg/kg per day, fasted)
Number of subjects: 600
Study 11464180 — intervention group
Group type: COMPARATOR
Intervention: Standard isotretinoin (1.0 mg/kg per day, fed, in two divided doses)
Number of subjects: 600
Study 9541686 — intervention group
Group type: COMPARATOR
Intervention: hCRF 0.66 micrograms/kg/h
Number of subjects: 17
Study 9541686 — intervention group
Group type: COMPARATOR
Intervention: hCRF 1 microgram/kg/h
Number of subjects: 17
Study 9541686 — intervention group
Group type: COMPARATOR
Intervention: hCRF 2 micrograms/kg/h
Number of subjects: 17
Study 9541686 — intervention group
Group type: COMPARATOR
Intervention: hCRF 4 micrograms/kg/h
Number of subjects: 17
Study 9541686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 7817832 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT)
Number of subjects: 875
Study 7817832 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of ERT
Number of subjects: 875
Study 7817832 — intervention group
Group type: EXPERIMENTAL
Intervention: Parity
Number of subjects: 875
Study 7817832 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethnic background
Number of subjects: 875
Study 7817832 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 875
Study 3048762 — intervention group
Group type: EXPERIMENTAL
Intervention: Alizapride plus dexamethasone (DXM)
Number of subjects: 39
Study 3048762 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus dexamethasone (DXM)
Number of subjects: 39
Study 31391003 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST) intervention
Number of subjects: 1035
Study 31391003 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline testing
Number of subjects: 1035
Study 31391003 — intervention group
Group type: EXPERIMENTAL
Intervention: HIVST intervention
Number of subjects: 1035
Study 31391003 — intervention group
Group type: COMPARATOR
Intervention: No baseline testing
Number of subjects: 1035
Study 29145868 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (Move for Well-being in School programme)
Number of subjects: 148
Study 29145868 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 148
Study 26152132 — intervention group
Group type: EXPERIMENTAL
Intervention: Selexipag 1,600 μg b.i.d. (1 x 1,600 μg tablet)
Number of subjects: 80
Study 26152132 — intervention group
Group type: COMPARATOR
Intervention: Selexipag 1,600 μg b.i.d. (8 x 200 μg tablets)
Number of subjects: 80
Study 23500307 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Doppler echocardiography (TDE)
Number of subjects: 71
Study 23500307 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachial pulse pressure (bPP)
Number of subjects: 71
Study 23500307 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic pulse wave velocity (PWV)
Number of subjects: 71
Study 23500307 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic pulse pressure (aoPP)
Number of subjects: 71
Study 23500307 — intervention group
Group type: EXPERIMENTAL
Intervention: Backward wave amplitude (Pb)
Number of subjects: 71
Study 23500307 — intervention group
Group type: EXPERIMENTAL
Intervention: Measures of pulsatile function added to TDE
Number of subjects: 71
Study 23500307 — intervention group
Group type: COMPARATOR
Intervention: TDE-based algorithm
Number of subjects: 71
Study 21679712 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 119
Study 19788023 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (12 microg)
Number of subjects: 79
Study 19788023 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline (0.5 mg)
Number of subjects: 79
Study 19788023 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 79
Study 16319215 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotation about an off-vertical axis (OVAR) at various speeds and tilt angles
Number of subjects: 6
Study 14985565 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir and ribavirin
Number of subjects: 41
Study 14985565 — intervention group
Group type: COMPARATOR
Intervention: ribavirin only
Number of subjects: 41
Study 11239724 — intervention group
Group type: EXPERIMENTAL
Intervention: Day drug abuse treatment
Number of subjects: 261
Study 11239724 — intervention group
Group type: COMPARATOR
Intervention: Residential drug abuse treatment
Number of subjects: 261
Study 9613543 — intervention group
Group type: EXPERIMENTAL
Intervention: Sympathetic nerve blocks
Number of subjects: 0
Study 9613543 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent sympathetic block with neurolytic or thermocoagulation techniques
Number of subjects: 0
Study 8291151 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive training course on interpretation of electrocardiography (8 hours)
Number of subjects: 107
Study 8291151 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 107
Study 8291151 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 107
Study 2498105 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate 40 mg
Number of subjects: 19
Study 2498105 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic isosorbide‐5‐mononitrate
Number of subjects: 19
Study 2498105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 31671400 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model incorporating six biomarkers (BHB, DHA, 1‐MedA, PdG, NAM, Xan)
Number of subjects: 124
Study 31671400 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind study for PTC and BTN
Number of subjects: 124
Study 27496852 — intervention group
Group type: EXPERIMENTAL
Intervention: Store-and-forward teledermatology intervention
Number of subjects: 103
Study 27496852 — intervention group
Group type: COMPARATOR
Intervention: Conventional referral (standard letters)
Number of subjects: 103
Study 26014444 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous unfractionated heparin (UFH) bolus (100 U/kg)
Number of subjects: 102
Study 26014444 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who failed to reach targeted ACT value of >300 seconds at T10
Number of subjects: 102
Study 22560048 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifrontal electrode placement (BFECT; n = 62)
Number of subjects: 122
Study 22560048 — intervention group
Group type: COMPARATOR
Intervention: Bitemporal electrode placement (BTECT; n = 60)
Number of subjects: 122
Study 20957515 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 260
Study 20957515 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 260
Study 20957515 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Fluoxetine and CBT (COMB)
Number of subjects: 260
Study 20957515 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 260
Study 19114912 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate
Number of subjects: 200
Study 19114912 — intervention group
Group type: COMPARATOR
Intervention: Nadroparin
Number of subjects: 200
Study 16924187 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxy report
Number of subjects: 47
Study 14755377 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment MM group (serum IL-16 level)
Number of subjects: 48
Study 14755377 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 48
Study 14755377 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with high IL-16 levels (>430 pg/ml)
Number of subjects: 48
Study 14755377 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment MM group (after chemotherapy)
Number of subjects: 48
Study 14755377 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease stage progression (from stage I to stage III)
Number of subjects: 48
Study 14755377 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment MM group (correlation with alpha1AT and IL-6)
Number of subjects: 48
Study 12774003 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol + placebo
Number of subjects: 349
Study 12774003 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol + IS‐MN
Number of subjects: 349
Study 10895566 — intervention group
Group type: EXPERIMENTAL
Intervention: Conceptually driven tests
Number of subjects: 2
Study 10895566 — intervention group
Group type: COMPARATOR
Intervention: Perceptually driven tests
Number of subjects: 2
Study 9151629 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine spray, twice daily for 30 days
Number of subjects: 8
Study 9151629 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06% chlorhexidine spray, twice daily for 30 days
Number of subjects: 8
Study 1407193 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic surfactant administration (n = 42)
Number of subjects: 81
Study 1407193 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic surfactant administration (n = 39)
Number of subjects: 81
Study 4004197 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (once-daily intramuscular injection) for a mean of 4.0 days
Number of subjects: 57
Study 4004197 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin (every 8 hours) for a mean of 4.5 days
Number of subjects: 57
Study 4004197 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (once-daily intramuscular injection)
Number of subjects: 57
Study 4004197 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin (every 8 hours)
Number of subjects: 57
Study 3147588 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 32
Study 3147588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 30281507 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized radial basis function network model for educational level classification
Number of subjects: 0
Study 30281507 — intervention group
Group type: COMPARATOR
Intervention: Other well-referenced machine learning models
Number of subjects: 0
Study 30929618 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral prevention program (CBP)
Number of subjects: 316
Study 26546305 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer Risk Check (CRC)
Number of subjects: 1452
Study 26546305 — intervention group
Group type: COMPARATOR
Intervention: Text-based control (online PDF file)
Number of subjects: 1452
Study 26000668 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg transmucous-buccal acetaminophen (B-APAP)
Number of subjects: 40
Study 26000668 — intervention group
Group type: COMPARATOR
Intervention: 1 g intravenous acetaminophen (iv-APAP)
Number of subjects: 40
Study 23097053 — intervention group
Group type: EXPERIMENTAL
Intervention: Violent video game
Number of subjects: 77
Study 23097053 — intervention group
Group type: COMPARATOR
Intervention: Nonviolent video game
Number of subjects: 77
Study 21709061 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg thrice per day)
Number of subjects: 44
Study 21709061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 19843490 — intervention group
Group type: EXPERIMENTAL
Intervention: MgV solution 500 mg
Number of subjects: 24
Study 19843490 — intervention group
Group type: EXPERIMENTAL
Intervention: MgV suspension 500 mg
Number of subjects: 24
Study 19843490 — intervention group
Group type: EXPERIMENTAL
Intervention: MgV enteric-coated tablets 500 mg
Number of subjects: 24
Study 16915900 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction dose of ketamine (6 mg/kg)
Number of subjects: 40
Study 16915900 — intervention group
Group type: COMPARATOR
Intervention: Low dose of ketamine (3 mg/kg)
Number of subjects: 40
Study 15044506 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic nose in 'top-note' mode
Number of subjects: 78
Study 15044506 — intervention group
Group type: EXPERIMENTAL
Intervention: Log VSC measurements
Number of subjects: 78
Study 15044506 — intervention group
Group type: EXPERIMENTAL
Intervention: Top-note score
Number of subjects: 78
Study 11581108 — intervention group
Group type: COMPARATOR
Intervention: Standard dose depot antipsychotic
Number of subjects: 0
Study 11581108 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot antipsychotics
Number of subjects: 0
Study 9645717 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% olopatadine
Number of subjects: 169
Study 9645717 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% olopatadine
Number of subjects: 169
Study 9645717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study 8164297 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g of wheat bran (WB)
Number of subjects: 34
Study 8164297 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g of wheat bran (WB)
Number of subjects: 34
Study 8164297 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g of vegetable fiber (VF)
Number of subjects: 34
Study 8164297 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g of vegetable fiber (VF)
Number of subjects: 34
Study 8164297 — intervention group
Group type: COMPARATOR
Intervention: 0 g of fiber (control)
Number of subjects: 34
Study 8164297 — intervention group
Group type: EXPERIMENTAL
Intervention: wheat bran (WB)
Number of subjects: 34
Study 8164297 — intervention group
Group type: EXPERIMENTAL
Intervention: vegetable fiber (VF)
Number of subjects: 34
Study 3344909 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended highly selective vagotomy
Number of subjects: 0
Study 3344909 — intervention group
Group type: COMPARATOR
Intervention: Highly selective vagotomy
Number of subjects: 0
Study 31498885 — intervention group
Group type: EXPERIMENTAL
Intervention: In-house developed TPS (Solo)
Number of subjects: 10
Study 28528342 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutricosmeceutical containing collagen bioactive peptides and antioxidants (50 mL daily)
Number of subjects: 120
Study 28528342 — intervention group
Group type: COMPARATOR
Intervention: Placebo (50 mL daily)
Number of subjects: 120
Study 25398726 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy (CIMT)
Number of subjects: 47
Study 25398726 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 47
Study 23220477 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (4.0 g/day; n = 11)
Number of subjects: 36
Study 23220477 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (1.2 g/day; n = 13)
Number of subjects: 36
Study 23220477 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 12)
Number of subjects: 36
Study 25090744 — intervention group
Group type: COMPARATOR
Intervention: Oral midazolam 0.6 mg/kg alone
Number of subjects: 30
Study 25090744 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam 0.6 mg/kg with nitrous oxide-oxygen inhalation
Number of subjects: 30
Study 18996631 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic retrotip
Number of subjects: 47
Study 18996631 — intervention group
Group type: COMPARATOR
Intervention: Microhead bur
Number of subjects: 47
Study 16974193 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 26
Study 16974193 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 26
Study 15074998 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 0
Study 15074998 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapy
Number of subjects: 0
Study 15074998 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 0
Study 15074998 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 11289484 — intervention group
Group type: EXPERIMENTAL
Intervention: Microalbuminuria cases (MA)
Number of subjects: 494
Study 11289484 — intervention group
Group type: COMPARATOR
Intervention: Normoalbuminuric control subjects
Number of subjects: 494
Study 9398709 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with insulin
Number of subjects: 100
Study 9398709 — intervention group
Group type: COMPARATOR
Intervention: Insulin therapy alone
Number of subjects: 100
Study 7956640 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroparetic patients
Number of subjects: 11
Study 7956640 — intervention group
Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 11
Study 2890951 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole 75 mg plus acetylsalicylic acid 325 mg (DP‐ASA)
Number of subjects: 2500